TY - JOUR
T1 - The prostate, lung, colon, and ovarian (PLCO) cancer screening trial
T2 - Status and promise
AU - Andriole, Gerald L.
AU - Reding, Douglas
AU - Hayes, Richard B.
AU - Prorok, Philip C.
AU - Gohagan, John K.
PY - 2004/7
Y1 - 2004/7
N2 - The Prostate, Lung, Cancer, and Ovarian Cancer Screening Trial is a randomized, multicenter, study evaluating whether screening for prostate, lung, colon, and ovarian cancer will reduce cancer-specific mortality. More than 155,000 participants have been identified and will be monitored through 2015. A biorepository of screened individuals and control participants has been created. Together, the data derived from the intervention and control arms and material in the biorepository provide a valuable resource to allow identification and testing of novel biomarkers for human disease.
AB - The Prostate, Lung, Cancer, and Ovarian Cancer Screening Trial is a randomized, multicenter, study evaluating whether screening for prostate, lung, colon, and ovarian cancer will reduce cancer-specific mortality. More than 155,000 participants have been identified and will be monitored through 2015. A biorepository of screened individuals and control participants has been created. Together, the data derived from the intervention and control arms and material in the biorepository provide a valuable resource to allow identification and testing of novel biomarkers for human disease.
KW - Biorepository
KW - Cancer screening
KW - Prevention
UR - http://www.scopus.com/inward/record.url?scp=3343019398&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2004.04.013
DO - 10.1016/j.urolonc.2004.04.013
M3 - Article
C2 - 15283897
AN - SCOPUS:3343019398
SN - 1078-1439
VL - 22
SP - 358
EP - 361
JO - Urologic Oncology: Seminars and Original Investigations
JF - Urologic Oncology: Seminars and Original Investigations
IS - 4
ER -